WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareBiotechnology
Best Biotech Stocks to Buy Now (2024)
Top biotech stocks in 2024 ranked by overall Zen Score. See the best biotech stocks to buy now, according to analyst forecasts for the biotechnology industry.

Industry: Biotechnology
Ticker
Company
Dividends Score
Market Cap
Dividend Yield
Payout Ratio
Last Dividend
Annual Dividend
Dividend Percentile
Dividend Dropped Count (L10Y)
Ex-dividend Date
Div. Payment Date
IFRX
INFLARX NV
$81.26MN/A0.00%N/AN/AN/AN/A
LQDA
LIQUIDIA CORP
$972.40MN/A0.00%N/AN/AN/AN/A
ATAI
ATAI LIFE SCIENCES NV
$340.35MN/A0.00%N/AN/AN/AN/A
GLMD
GALMED PHARMACEUTICALS LTD
$1.95MN/A0.00%N/AN/AN/AN/A
AUPH
AURINIA PHARMACEUTICALS INC
$729.40MN/A0.00%N/AN/AN/AN/A
BEAM
BEAM THERAPEUTICS INC
$1.89BN/A0.00%N/AN/AN/AN/A
CASI
CASI PHARMACEUTICALS INC
$37.39MN/A0.00%N/AN/AN/AN/A
NRBO
NEUROBO PHARMACEUTICALS INC
$18.54MN/A0.00%N/AN/AN/AN/A
BLUE
BLUEBIRD BIO INC
$98.40MN/A0.00%N/AN/AN/AN/A
HOTH
HOTH THERAPEUTICS INC
$5.33MN/A0.00%N/AN/AN/AN/A
MTEM
MOLECULAR TEMPLATES INC
$8.98MN/A0.00%N/AN/AN/AN/A
ARVN
ARVINAS INC
$2.23BN/A0.00%N/AN/AN/AN/A
MESO
MESOBLAST LTD
$761.10MN/A0.00%N/AN/AN/AN/A
CRBU
CARIBOU BIOSCIENCES INC
$340.49MN/A0.00%N/AN/AN/AN/A
YMAB
Y-MABS THERAPEUTICS INC
$750.78MN/A0.00%N/AN/AN/AN/A
LIFE
ATYR PHARMA INC
$111.11MN/A0.00%N/AN/AN/AN/A
CUE
CUE BIOPHARMA INC
$103.61MN/A0.00%N/AN/AN/AN/A
PGEN
PRECIGEN INC
$353.47MN/A0.00%N/AN/AN/AN/A
CCCC
C4 THERAPEUTICS INC
$462.37MN/A0.00%N/AN/AN/AN/A
ARDX
ARDELYX INC
$2.04BN/A0.00%N/AN/AN/AN/A
IKNA
IKENA ONCOLOGY INC
$63.70MN/A0.00%N/AN/AN/AN/A
CELZ
CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC
$5.96MN/A0.00%N/AN/AN/AN/A
LYRA
LYRA THERAPEUTICS INC
$245.69MN/A0.00%N/AN/AN/AN/A
QTTB
Q32 BIO INC
$82.65MN/A0.00%N/AN/AN/AN/A
ALLO
ALLOGENE THERAPEUTICS INC
$519.11MN/A0.00%N/AN/AN/AN/A
MIST
MILESTONE PHARMACEUTICALS INC
$89.82MN/A0.00%N/AN/AN/AN/A
PRTC
PURETECH HEALTH PLC
$773.99MN/A0.00%N/AN/AN/AN/A
XOMA
XOMA CORP
$288.09MN/A0.00%N/AN/AN/AN/A
NTLA
INTELLIA THERAPEUTICS INC
$2.27BN/A0.00%N/AN/AN/AN/A
PLUR
PLURI INC
$29.81MN/A0.00%N/AN/AN/AN/A
ARQT
ARCUTIS BIOTHERAPEUTICS INC
$774.51MN/A0.00%N/AN/AN/AN/A
DNLI
DENALI THERAPEUTICS INC
$2.39BN/A0.00%N/AN/AN/AN/A
LYEL
LYELL IMMUNOPHARMA INC
$599.67MN/A0.00%N/AN/AN/AN/A
SPRC
SCISPARC LTD
$890.42kN/A0.00%N/AN/AN/AN/A
IMNM
IMMUNOME INC
$940.18MN/A0.00%N/AN/AN/AN/A
KROS
KEROS THERAPEUTICS INC
$2.18BN/A0.00%N/AN/AN/AN/A
GLYC
GLYCOMIMETICS INC
$117.94MN/A0.00%N/AN/AN/AN/A
INO
INOVIO PHARMACEUTICALS INC
$282.78MN/A0.00%N/AN/AN/AN/A
MRNS
MARINUS PHARMACEUTICALS INC
$82.51MN/A0.00%N/AN/AN/AN/A
ABCL
ABCELLERA BIOLOGICS INC
$1.18BN/A0.00%N/AN/AN/AN/A
OVID
OVID THERAPEUTICS INC
$216.37MN/A0.00%N/AN/AN/AN/A
EDIT
EDITAS MEDICINE INC
$463.88MN/A0.00%N/AN/AN/AN/A
COCP
COCRYSTAL PHARMA INC
$16.58MN/A0.00%N/AN/AN/AN/A
PALI
PALISADE BIO INC
$6.59MN/A0.00%N/AN/AN/AN/A
CRNX
CRINETICS PHARMACEUTICALS INC
$3.28BN/A0.00%N/AN/AN/AN/A
ALEC
ALECTOR INC
$516.09MN/A0.00%N/AN/AN/AN/A
ALPN
ALPINE IMMUNE SCIENCES INC
$4.23BN/A0.00%N/AN/AN/AN/A
STTK
SHATTUCK LABS INC
$512.60MN/A0.00%N/AN/AN/AN/A
GERN
GERON CORP
$2.33BN/A0.00%N/AN/AN/AN/A
GBIO
GENERATION BIO CO
$210.73MN/A0.00%N/AN/AN/AN/A
MGNX
MACROGENICS INC
$978.31MN/A0.00%N/AN/AN/AN/A
PPBT
PURPLE BIOTECH LTD
$10.51MN/AN/AN/AN/AN/AN/A
ABSI
ABSCI CORP
$572.95MN/A0.00%N/AN/AN/AN/A
LUMO
LUMOS PHARMA INC
$24.00MN/A0.00%N/AN/AN/AN/A
KYMR
KYMERA THERAPEUTICS INC
$2.29BN/A0.00%N/AN/AN/AN/A
IMAB
I-MAB
$142.11MN/A0.00%N/AN/AN/AN/A
MRNA
MODERNA INC
$47.90BN/A0.00%N/AN/AN/AN/A
QURE
UNIQURE NV
$224.36MN/A0.00%N/AN/AN/AN/A
CVKD
CADRENAL THERAPEUTICS INC
$7.84MN/A0.00%N/AN/AN/AN/A
SXTP
60 DEGREES PHARMACEUTICALS INC
$2.43MN/A0.00%N/AN/AN/AN/A
NGNE
NEUROGENE INC
$470.80MN/A0.00%N/AN/AN/AN/A
BPMC
BLUEPRINT MEDICINES CORP
$6.71BN/A0.00%N/AN/AN/AN/A
ATOS
ATOSSA THERAPEUTICS INC
$208.00MN/A0.00%N/AN/AN/AN/A
EVGN
EVOGENE LTD
$35.92MN/A0.00%N/AN/AN/AN/A
ELVN
ENLIVEN THERAPEUTICS INC
$936.52MN/A0.00%N/AN/AN/AN/A
DTIL
PRECISION BIOSCIENCES INC
$72.76MN/A0.00%N/AN/AN/AN/A
CLDX
CELLDEX THERAPEUTICS INC
$2.38BN/A0.00%N/AN/AN/AN/A
DMAC
DIAMEDICA THERAPEUTICS INC
$113.87MN/A0.00%N/AN/AN/AN/A
SVRA
SAVARA INC
$649.99MN/A0.00%N/AN/AN/AN/A
TCRX
TSCAN THERAPEUTICS INC
$409.87MN/A0.00%N/AN/AN/AN/A
AVXL
ANAVEX LIFE SCIENCES CORP
$316.13MN/A0.00%N/AN/AN/AN/A
TBPH
THERAVANCE BIOPHARMA INC
$455.64MN/A0.00%N/AN/AN/AN/A
DNTH
DIANTHUS THERAPEUTICS INC
$757.15MN/A0.00%N/AN/AN/AN/A
NTBL
NOTABLE LABS LTD
$8.57MN/A0.00%N/AN/AN/AN/A
CRDF
CARDIFF ONCOLOGY INC
$157.43MN/A0.00%N/AN/AN/AN/A
TTNP
TITAN PHARMACEUTICALS INC
$6.29MN/A0.00%N/AN/AN/AN/A
MOLN
MOLECULAR PARTNERS AG
$130.76MN/A0.00%N/AN/AN/AN/A
LABP
LANDOS BIOPHARMA INC
$69.30MN/A0.00%N/AN/AN/AN/A
PMCB
PHARMACYTE BIOTECH INC
$17.86MN/A0.00%N/AN/AN/AN/A
FDMT
4D MOLECULAR THERAPEUTICS INC
$1.31BN/A0.00%N/AN/AN/AN/A
LSTA
LISATA THERAPEUTICS INC
$23.68MN/A0.00%N/AN/AN/AN/A
TRVI
TREVI THERAPEUTICS INC
$208.26MN/A0.00%N/AN/AN/AN/A
BOLT
BOLT BIOTHERAPEUTICS INC
$41.94MN/A0.00%N/AN/AN/AN/A
ETNB
89BIO INC
$862.08MN/A0.00%N/AN/AN/AN/A
TVTX
TRAVERE THERAPEUTICS INC
$476.38MN/A0.00%N/AN/AN/AN/A
AKRO
AKERO THERAPEUTICS INC
$1.11BN/A0.00%N/AN/AN/AN/A
SNSE
SENSEI BIOTHERAPEUTICS INC
$44.88MN/A0.00%N/AN/AN/AN/A
RIGL
RIGEL PHARMACEUTICALS INC
$210.45MN/A0.00%N/AN/AN/AN/A
ATXS
ASTRIA THERAPEUTICS INC
$524.32MN/A0.00%N/AN/AN/AN/A
DNA
GINKGO BIOWORKS HOLDINGS INC
$2.06BN/A0.00%N/AN/AN/AN/A
TERN
TERNS PHARMACEUTICALS INC
$351.71MN/A0.00%N/AN/AN/AN/A
ABIO
ARCA BIOPHARMA INC
$47.29MN/A0.00%N/AN/AN/AN/A
IOBT
IO BIOTECH INC
$97.50MN/A0.00%N/AN/AN/AN/A
CYCN
CYCLERION THERAPEUTICS INC
$8.01MN/A0.00%N/AN/AN/AN/A
CABA
CABALETTA BIO INC
$597.71MN/A0.00%N/AN/AN/AN/A
RXRX
RECURSION PHARMACEUTICALS INC
$2.07BN/A0.00%N/AN/AN/AN/A
MNKD
MANNKIND CORP
$1.19BN/A0.00%N/AN/AN/AN/A
PHAR
PHARMING GROUP NV
$671.07MN/A0.00%N/AN/AN/AN/A
URGN
UROGEN PHARMA LTD
$487.95MN/A0.00%N/AN/AN/AN/A
ADPT
ADAPTIVE BIOTECHNOLOGIES CORP
$436.73MN/A0.00%N/AN/AN/AN/A

Biotech Stocks FAQ

What are the best biotech stocks to buy right now in May 2024?

According to Zen Score, the 3 best biotechnology stocks to buy right now are:

1. Corcept Therapeutics (NASDAQ:CORT)


Corcept Therapeutics (NASDAQ:CORT) is the top biotech stock with a Zen Score of 65, which is 42 points higher than the biotech industry average of 23. It passed 21 out of 33 due diligence checks and has strong fundamentals. Corcept Therapeutics has seen its stock return 6.15% over the past year, overperforming other biotech stocks by 24 percentage points.

Corcept Therapeutics has an average 1 year price target of $40.67, an upside of 65.85% from Corcept Therapeutics's current stock price of $24.52.

Corcept Therapeutics stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 3 analysts covering Corcept Therapeutics, 66.67% have issued a Strong Buy rating, 33.33% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Incyte (NASDAQ:INCY)


Incyte (NASDAQ:INCY) is the second best biotech stock with a Zen Score of 64, which is 41 points higher than the biotech industry average of 23. It passed 20 out of 33 due diligence checks and has strong fundamentals. Incyte has seen its stock lose -20.99% over the past year, underperforming other biotech stocks by -3 percentage points.

Incyte has an average 1 year price target of $74.92, an upside of 39.37% from Incyte's current stock price of $53.76.

Incyte stock has a consensus Buy recommendation according to Wall Street analysts. Of the 13 analysts covering Incyte, 30.77% have issued a Strong Buy rating, 23.08% have issued a Buy, 46.15% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Amylyx Pharmaceuticals (NASDAQ:AMLX)


Amylyx Pharmaceuticals (NASDAQ:AMLX) is the third best biotech stock with a Zen Score of 63, which is 40 points higher than the biotech industry average of 23. It passed 20 out of 33 due diligence checks and has strong fundamentals. Amylyx Pharmaceuticals has seen its stock lose -92.77% over the past year, underperforming other biotech stocks by -74 percentage points.

Amylyx Pharmaceuticals has an average 1 year price target of $11.00, an upside of 441.87% from Amylyx Pharmaceuticals's current stock price of $2.03.

Amylyx Pharmaceuticals stock has a consensus Buy recommendation according to Wall Street analysts. Of the 5 analysts covering Amylyx Pharmaceuticals, 40% have issued a Strong Buy rating, 20% have issued a Buy, 40% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the biotech stocks with highest dividends?

Out of 3 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

1. Mei Pharma (NASDAQ:MEIP)


Mei Pharma (NASDAQ:MEIP) has an annual dividend yield of 57.19%, which is 42 percentage points higher than the biotech industry average of 15.03%.

Mei Pharma's dividend payout ratio of 58.9% indicates that its high dividend yield is sustainable for the long-term.

2. Novo Nordisk A S (NYSE:NVO)


Novo Nordisk A S (NYSE:NVO) has an annual dividend yield of 1.11%, which is -14 percentage points lower than the biotech industry average of 15.03%. Novo Nordisk A S's dividend payout is not stable, having dropped more than 10% nine times in the last 10 years. Novo Nordisk A S's dividend has shown consistent growth over the last 10 years.

Novo Nordisk A S's dividend payout ratio of 47.8% indicates that its dividend yield is sustainable for the long-term.

3. Bio Techne (NASDAQ:TECH)


Bio Techne (NASDAQ:TECH) has an annual dividend yield of 0.41%, which is -15 percentage points lower than the biotech industry average of 15.03%. Bio Techne's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Bio Techne's dividend has shown consistent growth over the last 10 years.

Bio Techne's dividend payout ratio of 22.7% indicates that its dividend yield is sustainable for the long-term.

Why are biotech stocks up?

Biotech stocks were up 1.07% in the last day, and up 6% over the last week. Ardelyx was the among the top gainers in the biotechnology industry, gaining 28.42% yesterday.

Ardelyx shares are trading higher after the company reported better-than-expected Q1 financial results.

What are the most undervalued biotech stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued biotech stocks right now are:

1. Incyte (NASDAQ:INCY)


Incyte (NASDAQ:INCY) is the most undervalued biotech stock based on WallStreetZen's Valuation Score. Incyte has a valuation score of 86, which is 73 points higher than the biotech industry average of 13. It passed 6 out of 7 valuation due diligence checks.

Incyte's stock has dropped -20.99% in the past year. It has underperformed other stocks in the biotech industry by -3 percentage points.

2. Royalty Pharma (NASDAQ:RPRX)


Royalty Pharma (NASDAQ:RPRX) is the second most undervalued biotech stock based on WallStreetZen's Valuation Score. Royalty Pharma has a valuation score of 86, which is 73 points higher than the biotech industry average of 13. It passed 6 out of 7 valuation due diligence checks.

Royalty Pharma's stock has dropped -19.61% in the past year. It has underperformed other stocks in the biotech industry by -1 percentage points.

3. Amylyx Pharmaceuticals (NASDAQ:AMLX)


Amylyx Pharmaceuticals (NASDAQ:AMLX) is the third most undervalued biotech stock based on WallStreetZen's Valuation Score. Amylyx Pharmaceuticals has a valuation score of 71, which is 58 points higher than the biotech industry average of 13. It passed 5 out of 7 valuation due diligence checks.

Amylyx Pharmaceuticals's stock has dropped -92.77% in the past year. It has underperformed other stocks in the biotech industry by -74 percentage points.

Are biotech stocks a good buy now?

50.1% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 80.46% over the next year.

What is the average p/e ratio of the biotechnology industry?

The average P/E ratio of the biotechnology industry is 6.05x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.